Progenics Pharmaceuticals (PGNX) 10-Q 8 Nov 18 2018 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 05, 2018
Document Information [Line Items]
Entity Registrant Name	Progenics Pharmaceuticals Inc
Entity Central Index Key	835,887
Trading Symbol	pgnx
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding (in shares)		84,542,514
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
ASSETS
Cash and cash equivalents	$ 148,851	$ 90,642
Accounts receivable, net	5,821	3,972
Other current assets	2,237	2,256
Total current assets	156,909	96,870
Property and equipment, net	3,977	4,122
Intangible assets, net	6,893	30,369
Goodwill	13,074	13,074
Restricted cash	1,529	1,522
Total assets	182,382	145,957
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable	629	3,359
Accrued expenses	7,650	9,555
Current portion of debt, net	8,216	2,445
Total current liabilities	16,495	15,359
Long-term debt, net	38,332	47,242
Contingent consideration liability	10,900	16,800
Deferred tax liability	26	1,575
Other liabilities	1,746	1,528
Total liabilities	67,499	82,504
Commitments and Contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value Authorized - 20,000 shares; issued and outstanding - none	0	0
Common stock, $0.0013 par value Authorized - 160,000 shares; issued - 84,742 shares in 2018 and 71,645 shares in 2017	110	93
Additional paid-in capital	712,111	609,829
Treasury stock at cost, 200 shares of common stock	(2,741)	(2,741)
Subscription receivable		(2,109)
Accumulated other comprehensive loss	(93)	(33)
Accumulated deficit	(594,504)	(541,586)
Total stockholders’ equity	114,883	63,453
Total liabilities and stockholders’ equity	$ 182,382	$ 145,957

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares shares in Thousands	Sep. 30, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	20,000	20,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0013	$ 0.0013
Common stock, shares authorized (in shares)	160,000	160,000
Common stock, shares issued (in shares)	84,742	71,645
Treasury stock at cost, shares (in shares)	200	200

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenue:
Revenue	$ 5,317	$ 2,697	$ 12,384	$ 7,809
Operating expenses:
Research and development	8,090	10,344	25,547	31,641
Selling, general and administrative	7,075	5,958	21,341	17,986
Intangible impairment charge	23,200		23,200
Change in contingent consideration liability	(8,000)	700	(5,900)	3,300
Total operating expenses	30,365	17,002	64,188	52,927
Operating loss	(25,048)	(14,305)	(51,804)	(45,118)
Other (expense) income:
Interest (expense) income, net	(762)	(1,047)	(2,698)	(3,230)
Total other (expense) income	(762)	(1,047)	(2,698)	(3,230)
Loss before income tax benefit	(25,810)	(15,352)	(54,502)	(48,348)
Income tax benefit	1,453		1,549
Net loss	$ (24,357)	$ (15,352)	$ (52,953)	$ (48,348)
Net loss per share - basic and diluted (in dollars per share)	$ (0.30)	$ (0.22)	$ (0.70)	$ (0.69)
Weighted-average shares - basic and diluted (in shares)	80,325	70,270	75,648	70,233
Royalty [Member]
Revenue:
Revenue	$ 5,169	$ 2,562	$ 11,757	$ 7,282
Product and Service, Other [Member]
Revenue:
Revenue	$ 148	$ 135	$ 627	$ 527

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Net loss	$ (24,357)	$ (15,352)	$ (52,953)	$ (48,348)
Other comprehensive loss:
Foreign currency translation adjustments	(4)	20	(60)	51
Comprehensive loss	$ (24,361)	$ (15,332)	$ (53,013)	$ (48,297)

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - 9 months ended Sep. 30, 2018 - USD ($) shares in Thousands, $ in Thousands	At-the-market Offering [Member]Common Stock [Member]	At-the-market Offering [Member]Common Stock Subscribed [Member]	At-the-market Offering [Member]Additional Paid-in Capital [Member]	At-the-market Offering [Member]Receivables from Stockholder [Member]	At-the-market Offering [Member]	Public Offering [Member]Common Stock [Member]	Public Offering [Member]Common Stock Subscribed [Member]	Public Offering [Member]Additional Paid-in Capital [Member]	Public Offering [Member]Retained Earnings [Member]	Public Offering [Member]AOCI Attributable to Parent [Member]	Public Offering [Member]Receivables from Stockholder [Member]	Public Offering [Member]Treasury Stock [Member]	Common Stock [Member]	Common Stock Subscribed [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Receivables from Stockholder [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Dec. 31, 2017													71,325	320					(200)
Balance at Dec. 31, 2017													$ 93		$ 609,829	$ (541,586)	$ (33)	$ (2,109)	$ (2,741)	$ 63,453
Net loss																(52,953)				(52,953)
Foreign currency translation adjustments																	(60)			(60)
Stock-based compensation expense															4,301					$ 4,301
Issuance of common stock (in shares)	4,230	(320)				9,091
Issuance of common stock	$ 5		$ 27,539	$ 2,109	$ 29,653	$ 12		$ 69,975
Exercise of stock options (in shares)													96							96
Exercise of stock options															467					$ 467
Balance (in shares) at Sep. 30, 2018													84,742						(200)
Balance at Sep. 30, 2018													$ 110		$ 712,111	(594,504)	$ (93)		$ (2,741)	114,883
Cumulative effect of ASU 2014-09 adoption																$ 35				$ 35

Condensed Consolidated Statem_4

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (Parentheticals) - Public Offering [Member] - Additional Paid-in Capital [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2018USD ($)
Underwriting discounts and commissions	$ 4,500
offering expenses	$ 513

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net loss	$ (24,357)	$ (52,953)	$ (48,348)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense		4,301	3,124
Depreciation and amortization		1,014	832
Non-cash interest expense		229	172
Deferred income tax		(1,549)
Intangible impairment charge	23,200	23,200
Change in fair value of contingent consideration liability	(8,000)	(5,900)	3,300
Other			10
Changes in assets and liabilities:
Accounts receivable		(1,813)	2,245
Other current assets		(1)	2,644
Accounts payable		(2,714)	527
Accrued expenses		(1,874)	(5,732)
Other liabilities		218	242
Net cash used in operating activities		(37,842)	(40,984)
Cash flows from investing activities:
Purchases of property and equipment		(595)	(263)
Proceeds from sale of fixed assets			37
Net cash used in investing activities		(595)	(226)
Cash flows from financing activities:
Net proceeds common stock	70,000
Return of estimated interest payment for noncontrolling interest			21
Proceeds from exercise of stock options		467	470
Repayment of debt		(3,368)
Net cash provided by financing activities		96,739	491
Effect of currency rate changes on cash, cash equivalents and restricted cash		(86)	93
Net decrease in cash, cash equivalents, and restricted cash		58,216	(40,626)
Cash, cash equivalents, and restricted cash at beginning of period		92,164	140,910
Cash, cash equivalents, and restricted cash at end of period	150,380	150,380	100,284
Cash, cash equivalents, and restricted cash information
Cash and cash equivalents at beginning of period		90,642
Restricted cash included in long-term assets at the beginning of period		1,522
Cash, cash equivalents, and restricted cash at beginning of period		92,164	140,910
Cash and cash equivalents at end of period	148,851	148,851
Restricted cash included in long-term assets at the end of period	1,529	1,529
Cash, cash equivalents, and restricted cash at end of period	150,380	150,380	100,284
Public Offering [Member]
Cash flows from financing activities:
Net proceeds common stock	70,000	69,987
At-the-market Offering [Member]
Cash flows from financing activities:
Net proceeds common stock	$ 4,800	$ 29,653

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Business Description and Accounting Policies [Text Block]	Note 1. Business Progenics Pharmaceuticals, Inc. and its subsidiaries (“the Company,” “Progenics,” “we” or “us”) is an oncology company focused on the development and commercialization of innovative targeted medicines and other technologies to target and treat cancer. Highlights of our recent progress include: ● AZEDRA ® approval. 131 555 12 first ● AZEDRA Launch. August 1, 2018. August, ® 3.2018. ® four © ® ® ● Pipeline Advancement ● We advanced our 1095 2 2019. 1095 1095 ● We reported topline results from our recently completed Phase 2/3 3 fourth ● We reported topline results of our recently completed Phase 3 1404. 3 1404 1404 not 1404. We consider opportunities for strategic collaborations, out-licenses, and other arrangements with biopharmaceutical companies involving proprietary research, development and clinical programs. We may Strategic partnerships ● RELISTOR ® ● Bayer AG (“Bayer”) has exclusive worldwide rights to develop and commercialize products using our PSMA antibody technology in combination with Bayer’s alpha-emitting radionuclides. Bayer is developing PSMA TTC, a thorium- 227 1 Our current principal sources of revenue from operations are royalty, development and commercial milestones from Bausch and Bayer. Royalty and further milestone payments from Bausch or Bayer depend on success in development and commercialization of RELISTOR and our PSMA antibody technology, respectively, which is dependent on many factors, such as Bausch or Bayer’s respective efforts, decisions by the FDA and other regulatory bodies, competition from drugs for the same or similar indications, and the outcome of clinical and other testing of the licensed products. We commenced principal operations in 1988, 1997, Liquidity At September 30, 2018, $148.9 $58.2 $90.6 December 31, 2017. one 10 may may During the third 2018, $70.0 9.1 $8.25 $4.8 0.6 $8.36 Note 10. Basis of Presentation Our interim condensed consolidated financial statements have been prepared in accordance with applicable presentation requirements, and accordingly, do not not Our interim condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto contained in our Annual Report on Form 10 December 31, 2017. not Reclassifications On January 1, 2018, No. 2016 18 2016 18” Statement of Cash Flows (Topic 230 Restricte d Cash No. 2016 15 2016 15” Statement of Cash Flows (Topic 230 nine September 30, 2017 Principles of Consolidation The condensed consolidated financial statements include the accounts of Progenics as well as its wholly-owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may Revenue Recognition In May 2014, 2014 09, Revenue from Contracts with Customers (Topic 606 2014 09” 606” 2014 09 January 1, 2018, not 2014 09 2017 January 1, 2018. no Based on the evaluation of our current contracts, revenue recognition is consistent under ASC 605 Revenue Recognition 606 Revenue from Contracts with Customers 2014 09 not January 1, 2018 $35 January 1, 2018, not Under this new guidance, we recognize revenue when our customers obtain control of the promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To account for arrangements that are within the scope of this new guidance, we perform the following five For contracts determined to be within the scope of Topic 606, not The transaction price is then determined and allocated to the identified performance obligations in proportion to their estimated fair value, which requires significant judgment. Variable consideration, which is estimated using the expected value method or the most likely amount method, is included in the transaction price only if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not For arrangements that include development, regulatory or sales milestone payments, we evaluate whether the milestones are probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not not not We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The following table summarizes our revenue streams from contracts with customers for the three nine September 30, 2018: Three months ended Nine months ended September 30, 2018 September 30, 2018 Royalty income $ 5,169 $ 11,757 Other revenue 148 627 Total revenue $ 5,317 $ 12,384 Royalty income Other revenue not We had receivable contract balances of $5.8 $4.0 September 30, 2018 December 31, 2017, Note 5 . Accounts Receivable Restricted Cash Restricted cash included in long-term assets of $1.5 September 30, 2018 December 31, 2017, Foreign Currency Translation Our international subsidiaries generally consider their respective local currency to be their functional currency. Assets and liabilities of these international subsidiaries are translated into U.S. dollars at quarter-end exchange rates and revenues and expenses are translated at average exchange rates during the quarter and year-to-date period. Foreign currency translation adjustments for the reported periods are included in accumulated other comprehensive loss (“AOCL”) in our condensed consolidated statements of comprehensive loss, and the cumulative effect is included in the stockholders’ equity section of our condensed consolidated balance sheets. Realized gains and losses denominated in foreign currencies are recorded in operating expenses in our condensed consolidated statements of operations and were not three nine September 30, 2018 2017. Property and Equipment Property and equipment is recorded at historical cost, net of accumulated depreciation and amortization of $2.5 $1.7 September 30, 2018 December 31, 2017, September 30, December 31, 2018 2017 Machinery and equipment $ 3,002 $ 2,516 Leasehold improvements 1,734 1,734 Computer equipment 719 714 Furniture and fixtures 878 874 Construction in progress 97 - Property and equipment, gross 6,430 5,838 Less - accumulated depreciation (2,453 ) (1,716 ) Property and equipment, net $ 3,977 $ 4,122

Note 2 - New Accounting Pronoun

Note 2 - New Accounting Pronouncements	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	Note 2. Recently Adopted In May 2014, 2014 09, Revenue from Contracts with Customers (Topic 606 2014 09” 606” 2014 09 January 1, 2018, not Note 1. Summary of Significant Accounting Policies In January 2016, No. 2016 01, Recognition and Measurement of Financial Assets and Financial Liabilities 2016 01” 2016 01 January 1, 2018. not not In November 2016, No. 2016 18 2016 18” Statement of Cash Flows (Topic 230 2016 18 January 1, 2018. nine September 30, 2017 In January 2017, No. 2017 01 2017 01” Business Combinations (Topic 805 January 1, 2018. not In January 2017, No. 2017 04 2017 04” Intangibles - Goodwill and Other (Topic 350 2 2 January 1, 2018. not Not In February 2016, No. 2016 02, Leases (Topic 842 2016 02” . 2016 02 2016 02 December 15, 2018, In August 2018, No. 2018 13, Fair Value Measurement - Disclosure Framework (Topic 820 2018 13” 2018 13 December 15, 2019.

Note 3 - Net Loss Per Share

Note 3 - Net Loss Per Share	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 3 . Net Loss Per Share Our basic net loss per share amounts have been computed by dividing net loss by the weighted-average number of common shares outstanding during the period. For the three nine September 30, 2018 2017, not The calculations of net loss per share, basic and diluted, are as follows (amounts in thousands, except per share data): Weighted-Average Shares Net Loss Outstanding Per Share (Numerator) (Denominator) Amount Three months ended September 30, 2018 Basic and diluted $ (24,357 ) 80,325 $ (0.30 ) Nine months ended September 30, 2018 Basic and diluted $ (52,953 ) 75,648 $ (0.70 ) Three months ended September 30, 2017 Basic and diluted $ (15,352 ) 70,270 $ (0.22 ) Nine months ended September 30, 2017 Basic and diluted $ (48,348 ) 70,233 $ (0.69 ) The following table summarizes anti-dilutive common shares or common shares where performance conditions have not Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Stock options 2,775 3,061 3,277 1,989 Contingent consideration liability 1,738 2,378 1,738 2,378 Total securities excluded 4,513 5,439 5,015 4,367

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 4 . Fair Value Measurements To estimate the fair values of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three ● Level 1 ● Level 2 1 ● Level 3 The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may We believe the carrying amounts of our cash equivalents, restricted cash, accounts receivable, other current assets, other assets, accounts payable and accrued expenses approximated their fair values as of September 30, 2018 December 31, 2017. We record the contingent consideration liability resulting from our acquisition of Molecular Insight Pharmaceuticals, Inc. (“MIP”) at fair value in accordance with Accounting Standards Codification (“ASC”) 820 820, Fair Value Measurement The following tables summarize each major class of our financial assets and liabilities measured at fair value on a recurring basis as of the dates indicated, classified by valuation hierarchy (in thousands): Fair Value Measurements at September 30, 2018 Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Balance at Identical Assets Inputs Inputs September 30, 2018 (Level 1) (Level 2) (Level 3) Assets: Money market funds $ 145,515 $ 145,515 $ - $ - Total assets $ 145,515 $ 145,515 $ - $ - Liabilities: Contingent consideration liability $ 10,900 $ - $ - $ 10,900 Total liabilities $ 10,900 $ - $ - $ 10,900 Fair Value Measurements at December 31, 2017 Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Balance at Identical Assets Inputs Inputs December 31, 2017 (Level 1) (Level 2) (Level 3) Assets: Money market funds $ 87,231 $ 87,231 $ - $ - Total assets $ 87,231 $ 87,231 $ - $ - Liabilities: Contingent consideration liability $ 16,800 $ - $ - $ 16,800 Total liabilities $ 16,800 $ - $ - $ 16,800 The contingent consideration liability of $10.9 September 30, 2018 Milestone payments due upon first Program Consideration Form of Payment at Progenics' Option AZEDRA $ 8,000 Cash or Progenics common stock 1404 10,000 Cash or Progenics common stock 1095 5,000 Cash or Progenics common stock $ 23,000 Net sales milestone payments due upon first Consideration Form of Payment at Progenics' Option $30 million $ 5,000 Cash or Progenics common stock $60 million 5,000 Cash or Progenics common stock $100 million 10,000 Cash or Progenics common stock $250 million 20,000 Cash or Progenics common stock $500 million 30,000 Cash or Progenics common stock $ 70,000 We consider this liability a Level 3 one Significant changes in any of the probabilities of success or the probabilities as to the periods in which milestones will be achieved, would result in a significantly higher or lower fair value measurement. We record the contingent consideration liability at fair value with changes in estimated fair values recorded in change in contingent consideration liability in our condensed consolidated statements of operations. The following table summarizes quantitative information and assumptions pertaining to the fair value measurement of the Level 3 September 30, 2018 December 31, 2017 ( $8.0 $5.9 three nine September 30, 2018, 1404, 3 one Fair Value at September 30, 2018 Valuation Technique Unobservable Input Assumption Contingent Consideration Liability: AZEDRA commercialization $ 7,000 Probability adjusted discounted Probability of success 90% cash flow model Period of expected milestone achievement 2019 Discount rate 10% 1095 commercialization 400 Probability adjusted discounted Probability of success 16% cash flow model Period of expected milestone achievement 2025 Discount rate 10% Net sales targets 3,500 Monte-Carlo simulation Probability of success 16% - 90% Discount rate 10% Total $ 10,900 Fair Value at December 31, 2017 Valuation Technique Unobservable Input Assumption Contingent Consideration Liability: AZEDRA commercialization $ 5,500 Probability adjusted discounted Probability of success 72% cash flow model Period of expected milestone achievement 2018 Discount rate 10% 1404 commercialization 4,500 Probability adjusted discounted Probability of success 59% cash flow model Period of expected milestone achievement 2020 Discount rate 10% 1095 commercialization 400 Probability adjusted discounted Probability of success 16% cash flow model Period of expected milestone achievement 2025 Discount rate 10% Net sales targets 6,400 Monte-Carlo simulation Probability of success 16% - 72% Discount rate 10% Total $ 16,800 For those financial instruments with significant Level 3 Liability - Contingent Consideration Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Balance at beginning of period $ 18,900 $ 16,800 $ 16,800 $ 14,200 Fair value change included in net loss (8,000 ) 700 (5,900 ) 3,300 Balance at end of period $ 10,900 $ 17,500 $ 10,900 $ 17,500 Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for liabilities held at the end of the reporting period $ (8,000 ) $ 700 $ (5,900 ) $ 3,300

Note 5 - Accounts Receivable

Note 5 - Accounts Receivable	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	Note 5 . Accounts Receivable Our accounts receivable represent amounts due to us from royalties, collaborators, and, to a small extent, sales of research reagents, and consisted of the following at September 30, 2018 December 31, 2017 ( September 30, December 31, 2018 2017 Royalties $ 5,169 $ 3,683 Other 652 289 Accounts receivable, net $ 5,821 $ 3,972

Note 6 - Goodwill, In-process R

Note 6 - Goodwill, In-process Research and Development, and Other Intangible Assets	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	Note 6 . Goodwill, In-Process Research and Development, and Other Intangible Assets The fair values of in-process research and development (“IPR&D”) and other identified intangible assets acquired in business combinations are capitalized. We utilize the “income method,” which applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected sales revenues and estimated costs or “replacement costs”, whichever is greater. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each IPR&D project and other identified intangible assets, independently. IPR&D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Other identified intangible assets, which include the technology asset acquired as part of the EXINI business combination, are amortized over the relevant estimated useful life. The IPR&D assets are tested for impairment at least annually or when a triggering event occurs that could indicate a potential impairment and any impairment loss is recognized in our condensed consolidated statements of operations. Based on the results from the recently completed 1404 3 one third 2018 $23.2 1404 In addition, upon the FDA approval of AZEDRA on July 30, 2018, $4.9 seven Goodwill represents excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not may one No September 30, 2018 2017. The following tables summarize the activity related to our goodwill and intangible assets (in thousands): Other Intangible Goodwill IPR&D Assets Balance at January 1, 2018 $ 13,074 $ 28,700 $ 1,669 Impairment - (23,200 ) - Amortization expense - (117 ) (159 ) Balance at September 30, 2018 $ 13,074 $ 5,383 $ 1,510 Other Intangible Goodwill IPR&D Assets Balance at January 1, 2017 $ 13,074 $ 28,700 $ 1,881 Amortization expense - - (159 ) Balance at September 30, 2017 $ 13,074 $ 28,700 $ 1,722

Note 7 - Accrued Expenses

Note 7 - Accrued Expenses	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	Note 7 . Accrued Expenses The carrying value of our accrued expenses approximates fair value, as it represents amounts that will be satisfied within one September 30, 2018 December 31, 2017 ( September 30, December 31, 2018 2017 Accrued clinical trial costs $ 2,163 $ 2,570 Accrued payroll and related costs 2,424 2,400 Accrued consulting and service fee expenses 1,241 1,860 Accrued legal and professional fees 1,114 1,022 Accrued contract manufacturing costs 252 666 Other 456 1,037 Accrued expenses $ 7,650 $ 9,555

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 8 . Commitments and Contingencies We are or may not one Abbreviated New Drug Application Litigations R ELISTOR Subcutaneous Injection - Mylan and Actavis Paragraph IV Certifications On or about October 6, 2015, November 20, 2015, December 22, 2015, December 23, 2015, four On or about October 27, 2015, January 5, 2016, January 8, 2016, three District Court Actions Progenics, Salix, Valeant (now Bausch Health Companies Inc., “Bausch”), and Wyeth filed suit against Mylan Pharmaceuticals, Inc. and Mylan Inc. in the District of New Jersey on November 19, 2015 ( 2:15 8180 8,247,425, 8,420,663, 8,552,025, 8,822,490 February 4, 2016, No. 9,180,125. January 4, 2016 ( 2:16 00035 8,247,425, 8,420,663, 8,552,025, 8,822,490 January 25, 2016, No. 9,180,125. September 1, 2017 ( 2:17 06714 No. 9,669,096 September 18, 2017, No. 9,492,445. Progenics, Salix, Bausch, and Wyeth filed suit against Actavis LLC, Actavis, Inc., Actavis Elizabeth LLC, and Allergan PLC fka Actavis PLC in the District of New Jersey on November 30, 2015 ( 2:15 08353 8,247,425, 8,420,663, 8,552,025, 8,822,490 February 18, 2016, No. 9,180,125. February 18, 2016 ( 2:16 00889 8,247,425, 8,420,663, 8,552,025, 8,822,490, 8,822,490 August 18, 2017 ( 2:17 07206 9,669,096 9,492,445 The 2:15 8180 2:16 00035 2:15 08353 2:16 00889 2:15 08180 May 1, 2018, 8 No. 8,552,025. May 23, 2018, 54 8 ’025 The 2:17 06714 2:17 07206 2:17 06714 2:15 8180 Settlement Agreement (Actavis) On May 25, 2018, No. 2:15 08180 No. 2:17 06714. 30 Under the Agreement, Plaintiffs grant Actavis a non-exclusive, royalty-free, non-transferable, non-sublicensable, limited license under the Patents-In-Suit to make, import, and sell each of the Actavis Products in the U.S. (the “License”) beginning on the earliest of (a) January 1, 2028; ( 21. 355 5 not 180 180 not not 180 181 third ® third not 180 first third ® 505 2 first No. 021964 ® ® first third Federal Circuit Appeal On May 25, 2018, On July 9, 2018, July 17, 2018, September 12, 2018. R ELISTOR Subcutaneous Injection - Par Paragraph IV Certification On or about July 15, 2017, District Court Actions Progenics, Salix, Bausch, and Wyeth filed suit against Par Sterile Products, LLC, Par Pharmaceutical, Inc., and Endo International plc in the District of New Jersey on August 25, 2017 ( 2:17 06449 8,247,425, 8,420,663, 8,552,025, 8,822,490, 9,180,125, 9,669,096 Progenics, Salix, Bausch, and Wyeth filed suit against Par Sterile Products, LLC, Par Pharmaceutical, Inc., and Endo International plc in the Southern District of New York on August 25, 2017 ( 1:17 06557 8,247,425, 8,420,663, 8,552,025, 8,822,490, 9,180,125, 9,669,096 November 30, 2017. Settlement Agreement On May 10, 2018, No. 17 06449 The Agreement provides for a full settlement and release by both Plaintiffs and Par of all claims that were or could have been asserted in the District Court Case and all resulting damages or other remedies. Plaintiffs and Par have agreed to and, in fact, filed a Stipulated Consent Judgment and Injunction after the execution of the Agreement. Plaintiffs and Par have further acknowledged and agreed that the 30 Under the Agreement, Plaintiffs grant Par a non-exclusive, royalty-free, non-transferable, non-sublicensable, limited license under the Patents-In-Suit to make, import, and sell the Par Products in the U.S., or make outside the U.S. solely for importation into the U.S. (the “License”) beginning on the earliest of (i) September 30, 2030; ( one hundred eighty-one 181 third 21. 355 5 ® third ® ® third not 180 first not one hundred fifty 150 R ELISTOR Tablets - Actavis Paragraph IV Certifications On or about October 24, 2016 October 24, 2017, two District Court Actions Progenics, Salix, Bausch, and Wyeth filed suit against Actavis Laboratories FL, Inc., Actavis LLC, Teva Pharmaceuticals USA, Inc., and Teva Pharmaceuticals Industries Ltd. in the District of New Jersey on December 6, 2016 ( 2:16 09038 8,420,663, 8,524,276, 8,956,651, 9,180,125, 9,314,461 Progenics, Salix, Bausch, and Wyeth filed suit against Actavis Laboratories FL, Inc., Actavis LLC, Teva Pharmaceuticals USA, Inc., and Teva Pharmaceuticals Industries Ltd. in the District of New Jersey on December 8, 2017 ( 2:17 12857 9,724,343 9,492,445 The 2:16 09038 2:17 12857 2:16 09038 European Opposition Proceedings In addition to the above described ANDA notifications, in October 2015, three EP1615646 September 24, 2015 EP2368553 September 29, 2015 September 30, 2015 EP2368554 September 24, 2015 On May 11, 2017, EP2368553 June 28, 2017, EP1615646 July 4, 2017, EP2368554 Progenics and Salix continue to cooperate closely to vigorously defend and enforce RELISTOR intellectual property rights. Pursuant to the RELISTOR license agreement between Progenics and Salix, Salix has the first

Note 9 - Non-recourse Long-term

Note 9 - Non-recourse Long-term Debt, Net	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 9. On November 4, 2016, $50.0 no 9.5%. Under the terms of the loan agreement, payments of interest and principal, if any, are made on the last day of each calendar quarter out of RELISTOR royalty payments received since the immediately-preceding payment date. On each payment date prior to March 31, 2018, March 31, 2018, 50% September 30, 2021, June 30, 2025. In connection with the Royalty-Backed Loan, the debt issuance costs have been recorded as a debt discount in our consolidated balance sheets and are being amortized and recorded as interest expense throughout the life of the loan using the effective interest method. The following tables summarize the components of the Royalty-Backed Loan in our condensed consolidated financial statements for the periods presented (in thousands): September 30, December 31, Condensed Consolidated Balance Sheets 2018 2017 Outstanding principal balance, current portion $ 8,551 $ 2,686 Unamortized debt discount, current portion (335 ) (241 ) Current portion of debt, net $ 8,216 $ 2,445 Outstanding principal balance, long-term portion $ 38,834 $ 48,066 Unamortized debt discount, long-term portion (502 ) (824 ) Long-term debt, net $ 38,332 $ 47,242 Three Months Ended Nine Months Ended September 30, September 30, Condensed Consolidated Statements of Operations 2018 2017 2018 2017 Interest expense $ 1,154 $ 1,205 $ 3,535 $ 3,603 Non-cash interest expense 92 62 229 172 Total interest expense included in interest (expense) income, net $ 1,246 $ 1,267 $ 3,764 $ 3,775 As of September 30, 2018, no

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 10 . Stockholders ’ Equity Common Stock and Preferred Stock We are authorized to issue 160.0 $0.0013, 20.0 $0.001. Shelf Registration During the first 2017, 3 No. 333 215454 $250 $250 $75 one third 2018, $70.0 9.1 $8.25 0.6 $4.8 $8.36 On October 12, 2018, 3 No. 333 227805 October 24, 2018. no $250 $250 $75 one October 2018 January 2017. may $75 3 Accumulated Other Comprehensive Loss The following table summarizes the components of AOCL at September 30, 2018 ( Foreign Currency Translation AOCL Balance at January 1, 2018 $ (33 ) $ (33 ) Foreign currency translation adjustment (60 ) (60 ) Balance at September 30, 2018 $ (93 ) $ (93 ) We did not nine September 30, 2018 2017.

Note 11 - Stock-based Compensat

Note 11 - Stock-based Compensation	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 1 1 . Stock-Based Compensation Equity Incentive Plans We adopted the following stockholder-approved equity incentive plans: ● The 1996 “1996 5,000,000 1996 2006. 1996 ● The 2005 “2005 11,450,000 2005 June 2018 2018 2005 2018 2005 ● The 2018 “2018 4,800,000 2018 March 27, 2028. The stock option plans provide that options may 100% may ten three five Stock Options The following table summarizes stock options activity for the nine September 30, 2018 ( Weighted Weighted Average Number Average Remaining of Shares Exercise Price Contractual Life Outstanding at January 1, 2018 5,535 $ 7.25 6.04 Granted 1,552 $ 6.94 Exercised (96 ) $ 4.85 Cancelled (331 ) $ 8.06 Expired (255 ) $ 16.07 Outstanding at September 30, 2018 6,405 $ 6.81 6.32 Exercisable at September 30, 2018 4,189 $ 6.42 4.99 Vested and expected to vest at September 30, 2018 5,942 $ 6.76 6.10 The weighted-average fair value of options granted during the three nine September 30, 2018 $4.38 $4.57 three nine September 30, 2017 $4.04 $7.11 The total intrinsic value (the excess of the market price over the exercise price) was approximately $3.3 $2.9 $3.3 September 30, 2018. three nine September 30, 2018 $173 three nine September 30, 2017 $2 $233 Stock-Based Compensation Expense We account for stock-based awards issued to employees in accordance with the provisions of ASC 718 718, Compensation – Stock Compensation three five 718 505 50 50 505, Equity 718, We estimated the fair value of the stock options granted on the date of grant using a Black-Scholes valuation model that used the weighted-average assumptions noted in the following table. The risk-free interest rate assumption we use is based upon United States Treasury interest rates appropriate for the expected life of the awards. The expected life (estimated period of time that we expect employees, directors, and consultants to hold their stock options) was estimated based on historical rates for three zero not not Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Risk-free interest rate 2.81 % 1.82 % 2.71 % 2.17 % Expected life (in years) 5.23 5.19 6.68 6.76 Expected volatility 62 % 74 % 69 % 72 % Expected dividend yield -- -- -- -- Stock-based compensation expense for the three nine September 30, 2018 2017 Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Research and development expenses $ 515 $ 380 $ 1,492 $ 941 Selling, general and administrative expenses 608 555 2,809 2,183 Total stock-based compensation expense $ 1,123 $ 935 $ 4,301 $ 3,124 At September 30, 2018, $6.4 2.2

Note 12 - Income Taxes

Note 12 - Income Taxes	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 12. We account for income taxes using the liability method in accordance with ASC 740 740, Income Taxes not During the three nine September 30, 2018, $1.5

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation Our interim condensed consolidated financial statements have been prepared in accordance with applicable presentation requirements, and accordingly, do not not Our interim condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto contained in our Annual Report on Form 10 December 31, 2017. not
Reclassification, Policy [Policy Text Block]	Reclassifications On January 1, 2018, No. 2016 18 2016 18” Statement of Cash Flows (Topic 230 Restricte d Cash No. 2016 15 2016 15” Statement of Cash Flows (Topic 230 nine September 30, 2017
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The condensed consolidated financial statements include the accounts of Progenics as well as its wholly-owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition In May 2014, 2014 09, Revenue from Contracts with Customers (Topic 606 2014 09” 606” 2014 09 January 1, 2018, not 2014 09 2017 January 1, 2018. no Based on the evaluation of our current contracts, revenue recognition is consistent under ASC 605 Revenue Recognition 606 Revenue from Contracts with Customers 2014 09 not January 1, 2018 $35 January 1, 2018, not Under this new guidance, we recognize revenue when our customers obtain control of the promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To account for arrangements that are within the scope of this new guidance, we perform the following five For contracts determined to be within the scope of Topic 606, not The transaction price is then determined and allocated to the identified performance obligations in proportion to their estimated fair value, which requires significant judgment. Variable consideration, which is estimated using the expected value method or the most likely amount method, is included in the transaction price only if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not For arrangements that include development, regulatory or sales milestone payments, we evaluate whether the milestones are probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not not not We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The following table summarizes our revenue streams from contracts with customers for the three nine September 30, 2018: Three months ended Nine months ended September 30, 2018 September 30, 2018 Royalty income $ 5,169 $ 11,757 Other revenue 148 627 Total revenue $ 5,317 $ 12,384 Royalty income Other revenue not We had receivable contract balances of $5.8 $4.0 September 30, 2018 December 31, 2017, Note 5 . Accounts Receivable
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash Restricted cash included in long-term assets of $1.5 September 30, 2018 December 31, 2017,
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation Our international subsidiaries generally consider their respective local currency to be their functional currency. Assets and liabilities of these international subsidiaries are translated into U.S. dollars at quarter-end exchange rates and revenues and expenses are translated at average exchange rates during the quarter and year-to-date period. Foreign currency translation adjustments for the reported periods are included in accumulated other comprehensive loss (“AOCL”) in our condensed consolidated statements of comprehensive loss, and the cumulative effect is included in the stockholders’ equity section of our condensed consolidated balance sheets. Realized gains and losses denominated in foreign currencies are recorded in operating expenses in our condensed consolidated statements of operations and were not three nine September 30, 2018 2017.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment is recorded at historical cost, net of accumulated depreciation and amortization of $2.5 $1.7 September 30, 2018 December 31, 2017, September 30, December 31, 2018 2017 Machinery and equipment $ 3,002 $ 2,516 Leasehold improvements 1,734 1,734 Computer equipment 719 714 Furniture and fixtures 878 874 Construction in progress 97 - Property and equipment, gross 6,430 5,838 Less - accumulated depreciation (2,453 ) (1,716 ) Property and equipment, net $ 3,977 $ 4,122

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three months ended Nine months ended September 30, 2018 September 30, 2018 Royalty income $ 5,169 $ 11,757 Other revenue 148 627 Total revenue $ 5,317 $ 12,384
Property, Plant and Equipment [Table Text Block]	September 30, December 31, 2018 2017 Machinery and equipment $ 3,002 $ 2,516 Leasehold improvements 1,734 1,734 Computer equipment 719 714 Furniture and fixtures 878 874 Construction in progress 97 - Property and equipment, gross 6,430 5,838 Less - accumulated depreciation (2,453 ) (1,716 ) Property and equipment, net $ 3,977 $ 4,122

Note 3 - Net Loss Per Share (Ta

Note 3 - Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Weighted-Average Shares Net Loss Outstanding Per Share (Numerator) (Denominator) Amount Three months ended September 30, 2018 Basic and diluted $ (24,357 ) 80,325 $ (0.30 ) Nine months ended September 30, 2018 Basic and diluted $ (52,953 ) 75,648 $ (0.70 ) Three months ended September 30, 2017 Basic and diluted $ (15,352 ) 70,270 $ (0.22 ) Nine months ended September 30, 2017 Basic and diluted $ (48,348 ) 70,233 $ (0.69 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Stock options 2,775 3,061 3,277 1,989 Contingent consideration liability 1,738 2,378 1,738 2,378 Total securities excluded 4,513 5,439 5,015 4,367

Note 4 - Fair Value Measureme_2

Note 4 - Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Fair Value Measurements at September 30, 2018 Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Balance at Identical Assets Inputs Inputs September 30, 2018 (Level 1) (Level 2) (Level 3) Assets: Money market funds $ 145,515 $ 145,515 $ - $ - Total assets $ 145,515 $ 145,515 $ - $ - Liabilities: Contingent consideration liability $ 10,900 $ - $ - $ 10,900 Total liabilities $ 10,900 $ - $ - $ 10,900 Fair Value Measurements at December 31, 2017 Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Balance at Identical Assets Inputs Inputs December 31, 2017 (Level 1) (Level 2) (Level 3) Assets: Money market funds $ 87,231 $ 87,231 $ - $ - Total assets $ 87,231 $ 87,231 $ - $ - Liabilities: Contingent consideration liability $ 16,800 $ - $ - $ 16,800 Total liabilities $ 16,800 $ - $ - $ 16,800
Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]	Program Consideration Form of Payment at Progenics' Option AZEDRA $ 8,000 Cash or Progenics common stock 1404 10,000 Cash or Progenics common stock 1095 5,000 Cash or Progenics common stock $ 23,000 Consideration Form of Payment at Progenics' Option $30 million $ 5,000 Cash or Progenics common stock $60 million 5,000 Cash or Progenics common stock $100 million 10,000 Cash or Progenics common stock $250 million 20,000 Cash or Progenics common stock $500 million 30,000 Cash or Progenics common stock $ 70,000
Fair Value Inputs, Assets and Liabilities, Quantitative Information [Table Text Block]	Fair Value at September 30, 2018 Valuation Technique Unobservable Input Assumption Contingent Consideration Liability: AZEDRA commercialization $ 7,000 Probability adjusted discounted Probability of success 90% cash flow model Period of expected milestone achievement 2019 Discount rate 10% 1095 commercialization 400 Probability adjusted discounted Probability of success 16% cash flow model Period of expected milestone achievement 2025 Discount rate 10% Net sales targets 3,500 Monte-Carlo simulation Probability of success 16% - 90% Discount rate 10% Total $ 10,900 Fair Value at December 31, 2017 Valuation Technique Unobservable Input Assumption Contingent Consideration Liability: AZEDRA commercialization $ 5,500 Probability adjusted discounted Probability of success 72% cash flow model Period of expected milestone achievement 2018 Discount rate 10% 1404 commercialization 4,500 Probability adjusted discounted Probability of success 59% cash flow model Period of expected milestone achievement 2020 Discount rate 10% 1095 commercialization 400 Probability adjusted discounted Probability of success 16% cash flow model Period of expected milestone achievement 2025 Discount rate 10% Net sales targets 6,400 Monte-Carlo simulation Probability of success 16% - 72% Discount rate 10% Total $ 16,800
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Liability - Contingent Consideration Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Balance at beginning of period $ 18,900 $ 16,800 $ 16,800 $ 14,200 Fair value change included in net loss (8,000 ) 700 (5,900 ) 3,300 Balance at end of period $ 10,900 $ 17,500 $ 10,900 $ 17,500 Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for liabilities held at the end of the reporting period $ (8,000 ) $ 700 $ (5,900 ) $ 3,300

Note 5 - Accounts Receivable (T

Note 5 - Accounts Receivable (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	September 30, December 31, 2018 2017 Royalties $ 5,169 $ 3,683 Other 652 289 Accounts receivable, net $ 5,821 $ 3,972

Note 6 - Goodwill, In-process_2

Note 6 - Goodwill, In-process Research and Development, and Other Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Intangible Assets and Goodwill [Table Text Block]	Other Intangible Goodwill IPR&D Assets Balance at January 1, 2018 $ 13,074 $ 28,700 $ 1,669 Impairment - (23,200 ) - Amortization expense - (117 ) (159 ) Balance at September 30, 2018 $ 13,074 $ 5,383 $ 1,510 Other Intangible Goodwill IPR&D Assets Balance at January 1, 2017 $ 13,074 $ 28,700 $ 1,881 Amortization expense - - (159 ) Balance at September 30, 2017 $ 13,074 $ 28,700 $ 1,722

Note 7 - Accrued Expenses (Tabl

Note 7 - Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	September 30, December 31, 2018 2017 Accrued clinical trial costs $ 2,163 $ 2,570 Accrued payroll and related costs 2,424 2,400 Accrued consulting and service fee expenses 1,241 1,860 Accrued legal and professional fees 1,114 1,022 Accrued contract manufacturing costs 252 666 Other 456 1,037 Accrued expenses $ 7,650 $ 9,555

Note 9 - Non-recourse Long-te_2

Note 9 - Non-recourse Long-term Debt, Net (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Long-term Debt Instruments [Table Text Block]	September 30, December 31, Condensed Consolidated Balance Sheets 2018 2017 Outstanding principal balance, current portion $ 8,551 $ 2,686 Unamortized debt discount, current portion (335 ) (241 ) Current portion of debt, net $ 8,216 $ 2,445 Outstanding principal balance, long-term portion $ 38,834 $ 48,066 Unamortized debt discount, long-term portion (502 ) (824 ) Long-term debt, net $ 38,332 $ 47,242 Three Months Ended Nine Months Ended September 30, September 30, Condensed Consolidated Statements of Operations 2018 2017 2018 2017 Interest expense $ 1,154 $ 1,205 $ 3,535 $ 3,603 Non-cash interest expense 92 62 229 172 Total interest expense included in interest (expense) income, net $ 1,246 $ 1,267 $ 3,764 $ 3,775

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Foreign Currency Translation AOCL Balance at January 1, 2018 $ (33 ) $ (33 ) Foreign currency translation adjustment (60 ) (60 ) Balance at September 30, 2018 $ (93 ) $ (93 )

Note 11 - Stock-based Compens_2

Note 11 - Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted Weighted Average Number Average Remaining of Shares Exercise Price Contractual Life Outstanding at January 1, 2018 5,535 $ 7.25 6.04 Granted 1,552 $ 6.94 Exercised (96 ) $ 4.85 Cancelled (331 ) $ 8.06 Expired (255 ) $ 16.07 Outstanding at September 30, 2018 6,405 $ 6.81 6.32 Exercisable at September 30, 2018 4,189 $ 6.42 4.99 Vested and expected to vest at September 30, 2018 5,942 $ 6.76 6.10
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Risk-free interest rate 2.81 % 1.82 % 2.71 % 2.17 % Expected life (in years) 5.23 5.19 6.68 6.76 Expected volatility 62 % 74 % 69 % 72 % Expected dividend yield -- -- -- --
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2018 2017 2018 2017 Research and development expenses $ 515 $ 380 $ 1,492 $ 941 Selling, general and administrative expenses 608 555 2,809 2,183 Total stock-based compensation expense $ 1,123 $ 935 $ 4,301 $ 3,124

Note 1 - Summary of Significa_3

Note 1 - Summary of Significant Accounting Policies (Details Textual) $ / shares in Units, $ in Thousands, shares in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2018USD ($)$ / shares	Sep. 30, 2017USD ($)	Jan. 01, 2018USD ($)	Dec. 31, 2017USD ($)
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 148,851	$ 148,851			$ 90,642
Cash and Cash Equivalents, Period Increase (Decrease), Total		$ 58,200
Number of Years Cash is Sufficient to Fund Operations		1 year
Proceeds from Issuance of Common Stock	70,000
Cumulative Effect of New Accounting Principle in Period of Adoption	35	$ 35
Accounts Receivable, Net, Current, Total	5,821	5,821			3,972
Restricted Cash and Cash Equivalents, Noncurrent, Total	1,529	1,529			1,522
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance	2,453	$ 2,453			$ 1,716
Number of Operating Segments		1
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	35	$ 35
Accounting Standards Update 2014-09 [Member]
Accounts Receivable, Net, Current, Total				$ 35
Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption				$ 35
Public Offering [Member]
Proceeds from Issuance of Common Stock	$ 70,000	$ 69,987
Stock Issued During Period, Shares, New Issues | shares	9.1
Shares Issued, Price Per Share | $ / shares	$ 8.25	$ 8.25
At-the-market Offering [Member]
Proceeds from Issuance of Common Stock	$ 4,800	$ 29,653
Stock Issued During Period, Shares, New Issues | shares	0.6
Shares Issued, Price Per Share | $ / shares	$ 8.36	$ 8.36

Note 1 - Summary of Significa_4

Note 1 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenue	$ 5,317	$ 2,697	$ 12,384	$ 7,809
Royalty [Member]
Revenue	5,169	2,562	11,757	7,282
Product and Service, Other [Member]
Revenue	$ 148	$ 135	$ 627	$ 527

Note 1 - Summary of Significa_5

Note 1 - Summary of Significant Accounting Policies - Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Property and equipment, gross	$ 6,430	$ 5,838
Less - accumulated depreciation	(2,453)	(1,716)
Property and equipment, net	3,977	4,122
Machinery and Equipment [Member]
Property and equipment, gross	3,002	2,516
Leasehold Improvements [Member]
Property and equipment, gross	1,734	1,734
Computer Equipment [Member]
Property and equipment, gross	719	714
Furniture and Fixtures [Member]
Property and equipment, gross	878	874
Construction in Progress [Member]
Property and equipment, gross	$ 97

Note 3 - Net Loss Per Share - C

Note 3 - Net Loss Per Share - Calculations of Net Loss Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Basic and diluted, net loss attributable to Progenics	$ (24,357)	$ (15,352)	$ (52,953)	$ (48,348)
Basic and diluted, weighted average shares outstanding (in shares)	80,325	70,270	75,648	70,233
Basic and diluted, per share amount (in dollars per share)	$ (0.30)	$ (0.22)	$ (0.70)	$ (0.69)

Note 3 - Net Loss Per Share -_2

Note 3 - Net Loss Per Share - Common Shares Excluded From Calculation of Diluted Net Loss Per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Antidilutive securities (in shares)	4,513	5,439	5,015	4,367
Employee Stock Option [Member]
Antidilutive securities (in shares)	2,775	3,061	3,277	1,989
Contingent Consideration Liability [Member]
Antidilutive securities (in shares)	1,738	2,378	1,738	2,378

Note 4 - Fair Value Measureme_3

Note 4 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Business Combination, Contingent Consideration, Liability, Noncurrent	$ 10,900		$ 10,900		$ 16,800
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	$ (8,000)	$ 700	$ (5,900)	$ 3,300

Note 4 - Fair Value Measureme_4

Note 4 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Money market funds	$ 145,515	$ 87,231
Total assets	145,515	87,231
Contingent consideration liability	10,900	16,800
Total liabilities	10,900	16,800
Fair Value, Inputs, Level 1 [Member]
Money market funds	145,515	87,231
Total assets	145,515	87,231
Contingent consideration liability
Total liabilities
Fair Value, Inputs, Level 2 [Member]
Money market funds
Total assets
Contingent consideration liability
Total liabilities
Fair Value, Inputs, Level 3 [Member]
Money market funds
Total assets
Contingent consideration liability	10,900	16,800
Total liabilities	$ 10,900	$ 16,800

Note 4 - Fair Value Measureme_5

Note 4 - Fair Value Measurements - Contingent Consideration Liabilities (Details) $ in Millions	Sep. 30, 2018USD ($)
Molecular Insight Pharmaceuticals, Inc. [Member] | Milestone Payment upon First Commercial Sale [Member]
Contingent Consideration	$ 23
Molecular Insight Pharmaceuticals, Inc. [Member] | Milestone Payment upon Achievement of All Levels of Net Sales [Member]
Contingent Consideration	70
Molecular Insight Pharmaceuticals, Inc. [Member] | Milestone Payment upon Achievement of Net Sales Level 2 [Member]
Contingent Consideration	5
Molecular Insight Pharmaceuticals, Inc. [Member] | Milestone Payment upon Achievement of Net Sales Level 3 [Member]
Contingent Consideration	10
Molecular Insight Pharmaceuticals, Inc. [Member] | Milestone Payment upon Achievement of Net Sales Level 4 [Member]
Contingent Consideration	20
Molecular Insight Pharmaceuticals, Inc. [Member] | Milestone Payment upon Achievement of Net Sales Level 5 [Member]
Contingent Consideration	30
Milestone Payment upon Achievement of Net Sales Level 1 [Member] | Milestone Payment upon Achievement of All Levels of Net Sales [Member]
Contingent Consideration	5
AZEDRA Program [Member] | Molecular Insight Pharmaceuticals, Inc. [Member] | Milestone Payment upon First Commercial Sale [Member]
Contingent Consideration	8
The 1404 Program [Member] | Molecular Insight Pharmaceuticals, Inc. [Member] | Milestone Payment upon First Commercial Sale [Member]
Contingent Consideration	10
The 1095 Program[Member] | Molecular Insight Pharmaceuticals, Inc. [Member] | Milestone Payment upon First Commercial Sale [Member]
Contingent Consideration	$ 5

Note 4 - Fair Value Measureme_6

Note 4 - Fair Value Measurements - Quantitative Information for Fair Value Measurement of Level 3 (Details)	Sep. 30, 2018USD ($)	Dec. 31, 2017USD ($)
Fair value	$ 10,900,000	$ 16,800,000
AZEDRA Commercialization [Member]
Fair value	$ 7,000,000	$ 5,500,000
Measurement input	2,019	2,018
AZEDRA Commercialization [Member] | Measurement Input, Probability of Success [Member]
Measurement input	0.9	0.72
AZEDRA Commercialization [Member] | Measurement Input, Discount Rate [Member]
Measurement input	0.1	0.1
MIP - 1404 Commercialization [Member]
Fair value	$ 400,000	$ 4,500,000
Measurement input	2,025	2,020
MIP - 1404 Commercialization [Member] | Measurement Input, Probability of Success [Member]
Measurement input	0.16	0.59
MIP - 1404 Commercialization [Member] | Measurement Input, Discount Rate [Member]
Measurement input	0.1	0.1
Net sales targets [Member]
Fair value	$ 3,500,000	$ 6,400,000
Net sales targets [Member] | Measurement Input, Probability of Success [Member] | Minimum [Member]
Measurement input	0.16	0.16
Net sales targets [Member] | Measurement Input, Probability of Success [Member] | Maximum [Member]
Measurement input	0.9	0.72
Net sales targets [Member] | Measurement Input, Discount Rate [Member]
Measurement input		0.1
MIP-1095 Commercialization [Member]
Fair value		$ 4
Measurement input	10	2,025
MIP-1095 Commercialization [Member] | Measurement Input, Probability of Success [Member]
Measurement input		0.16
MIP-1095 Commercialization [Member] | Measurement Input, Discount Rate [Member]
Measurement input		0.1

Note 4 - Fair Value Measureme_7

Note 4 - Fair Value Measurements - Summary of Activities in Financial Instruments With Level 3 Inputs (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Balance	$ 18.9	$ 16.8	$ 16.8	$ 14.2
Fair value change included in net loss	(8)	0.7	(5.9)	3.3
Balance	10.9	17.5	10.9	17.5
Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for liabilities held at the end of the reporting period	$ (8)	$ 0.7	$ (5.9)	$ 3.3

Note 5 - Accounts Receivable -

Note 5 - Accounts Receivable - Summary of Accounts Receivable (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Accounts receivable, net	$ 5,821	$ 3,972
Royalties [Member]
Accounts receivable, net	5,169	3,683
Other [Member]
Accounts receivable, net	$ 652	$ 289

Note 6 - Goodwill, In-process_3

Note 6 - Goodwill, In-process Research and Development, and Other Intangible Assets (Details Textual) $ in Thousands	Jul. 30, 2018USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)		$ 23,200		$ 23,200
Number of Reporting Units				1
Goodwill, Impairment Loss				$ 0	$ 0
AZEDRA Program [Member]
Finite-Lived Intangible Assets, Gross, Total	$ 4,900
Finite-Lived Intangible Asset, Useful Life	7 years
The 1404 Program [Member]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)		$ 23,200

Note 6 - Goodwill, In-process_4

Note 6 - Goodwill, In-process Research and Development, and Other Intangible Assets - Summary of Goodwill and Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Goodwill	$ 13,074	$ 13,074	$ 13,074	$ 13,074	$ 13,074	$ 13,074
Impairment	(23,200)		(23,200)
Amortization expense
In Process Research and Development [Member]
Balance, Finite-lived Intangible Assets			28,700	28,700
Impairment			(23,200)
Amortization expense, Finite-lived Intangible Assets			(117)
Balance, Finite-lived Intangible Assets	5,383	28,700	5,383	28,700
Other Intangible Assets [Member]
Balance, Finite-lived Intangible Assets			1,669	1,881
Amortization expense, Finite-lived Intangible Assets			(159)	(159)
Balance, Finite-lived Intangible Assets	$ 1,510	$ 1,722	$ 1,510	$ 1,722

Note 7 - Accrued Expenses - Sum

Note 7 - Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Accrued clinical trial costs	$ 2,163	$ 2,570
Accrued payroll and related costs	2,424	2,400
Accrued consulting and service fee expenses	1,241	1,860
Accrued legal and professional fees	1,114	1,022
Accrued contract manufacturing costs	252	666
Other	456	1,037
Accrued expenses	$ 7,650	$ 9,555

Note 9 - Non-recourse Long-te_3

Note 9 - Non-recourse Long-term Debt, Net (Details Textual) - Royalty-backed Loan [Member] - USD ($) $ in Millions	Nov. 04, 2016	Sep. 30, 2018
Proceeds from Issuance of Long-term Debt, Total	$ 50
Debt Instrument, Interest Rate, Stated Percentage	9.50%
Percentage of Royalty Payments in Excess of Accrued Loan Interest to be Applied to Principal		50.00%

Note 9 - Non-recourse Long-te_4

Note 9 - Non-recourse Long-term Debt, Net - Summary of Royalty-backed Loan (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Current portion of debt, net	$ 8,216		$ 8,216		$ 2,445
Long-term debt, net	38,332		38,332		47,242
Royalty-backed Loan [Member]
Outstanding principal balance, current portion	8,551		8,551		2,686
Unamortized debt discount, current portion	(335)		(335)		(241)
Current portion of debt, net	8,216		8,216		2,445
Outstanding principal balance, long-term portion	38,834		38,834		48,066
Unamortized debt discount, long-term portion	(502)		(502)		(824)
Long-term debt, net	38,332		38,332		$ 47,242
Interest expense	1,154	$ 1,205	3,535	$ 3,603
Non-cash interest expense	92	62	229	172
Total interest expense included in interest (expense) income, net	$ 1,246	$ 1,267	$ 3,764	$ 3,775

Note 10 - Stockholders' Equit_2

Note 10 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	Oct. 12, 2018	Sep. 30, 2018	Mar. 31, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Common Stock, Shares Authorized		160,000		160,000		160,000
Common Stock, Par or Stated Value Per Share		$ 0.0013		$ 0.0013		$ 0.0013
Preferred Stock, Shares Authorized		20,000		20,000		20,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001		$ 0.001		$ 0.001
Replacement Shelf Registration			$ 250,000
Common Stock Sales Agreement with Agent, Maximum Aggregate Offering Price			$ 75,000
Proceeds from Issuance of Common Stock		$ 70,000
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax				$ 0	$ 0
Subsequent Event [Member]
Replacement Shelf Registration	$ 250,000
Common Stock Sales Agreement with Agent, Maximum Aggregate Offering Price	$ 75,000
Public Offering [Member]
Proceeds from Issuance of Common Stock		$ 70,000		$ 69,987
Stock Issued During Period, Shares, New Issues		9,100
Shares Issued, Price Per Share		$ 8.25		$ 8.25
At-the-market Offering [Member]
Proceeds from Issuance of Common Stock		$ 4,800		$ 29,653
Stock Issued During Period, Shares, New Issues		600
Shares Issued, Price Per Share		$ 8.36		$ 8.36
Payments of Stock Issuance Costs		$ 4,800

Note 10 - Stockholders' Equit_3

Note 10 - Stockholders' Equity - Components of Accumulated Other Comprehensive Loss (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2018USD ($)
Balance	$ 63,453
Balance	114,883
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance	(33)
Foreign currency translation adjustment	(60)
Balance	(93)
AOCI Attributable to Parent [Member]
Balance	(33)
Foreign currency translation adjustment	(60)
Balance	$ (93)

Note 11 - Stock-based Compens_3

Note 11 - Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 4.38	$ 4.04	$ 4.57	$ 7.11
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	$ 3,300		$ 3,300
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	2,900		2,900
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	3,300		3,300
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 173	$ 2	$ 173	$ 233
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 6,400		$ 6,400
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			2 years 73 days
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
Employee Stock Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			3 years
Employee Stock Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			5 years
The 1996 Amended Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	5,000,000		5,000,000
The 2005 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	11,450,000		11,450,000
The 2018 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	4,800,000		4,800,000

Note 11 - Stock-based Compens_4

Note 11 - Stock-based Compensation - Summary of Option Activity Under the Plans (Details) - $ / shares shares in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Outstanding, shares (in shares)	5,535
Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 7.25
Outstanding, Weighted Average Remaining Contractual Life (Year)	6 years 116 days	6 years 14 days
Granted, shares (in shares)	1,552
Granted, Weighted Average Exercise Price (in dollars per share)	$ 6.94
Exercised, shares (in shares)	(96)
Exercised, Weighted Average Exercise Price (in dollars per share)	$ 4.85
Cancelled, shares (in shares)	(331)
Cancelled, Weighted Average Exercise Price (in dollars per share)	$ 8.06
Expired, shares (in shares)	(255)
Expired, Weighted Average Exercise Price (in dollars per share)	$ 16.07
Outstanding, shares (in shares)	6,405	5,535
Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 6.81	$ 7.25
Exercisable, shares (in shares)	4,189
Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 6.42
Exercisable, Weighted Average Remaining Contractual Life (Year)	4 years 361 days
Vested and expected to vest, shares (in shares)	5,942
Vested and expected to vest, Weighted Average Exercise Price (in dollars per share)	$ 6.76
Vested and expected to vest, Weighted Average Remaining Contractual Life (Year)	6 years 36 days

Note 11 - Stock-based Compens_5

Note 11 - Stock-based Compensation - Assumptions Used in Computing the Fair Value of Option Grants (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Risk-free interest rate	2.81%	1.82%	2.71%	2.17%
Expected life (in years) (Year)	5 years 83 days	5 years 69 days	6 years 248 days	6 years 277 days
Expected volatility	62.00%	74.00%	69.00%	72.00%
Expected dividend yield	0.00%	0.00%	0.00%

Note 11 - Stock-based Compens_6

Note 11 - Stock-based Compensation - Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Total compensation expense recognized	$ 1,123	$ 935	$ 4,301	$ 3,124
Research and Development Expense [Member]
Total compensation expense recognized	515	380	1,492	941
Selling, General and Administrative Expenses [Member]
Total compensation expense recognized	$ 608	$ 555	$ 2,809	$ 2,183

Note 12 - Income Taxes (Details

Note 12 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Tax Expense (Benefit), Total	$ (1,453)		$ (1,549)